Yige Wu

Beijing Center for Disease Prevention and Control — China

Medicine · Health Sciences

24h-index6.2kcitations74works14.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Renal cell carcinoma treatment(26), Cancer Genomics and Diagnostics(19), Ferroptosis and cancer prognosis(14), RNA modifications and cancer(6), Antibiotic Resistance in Bacteria(4)

Publications67 total

Comprehensive antibiotic resistome comparison of Escherichia coli from irritable bowel syndrome and ulcerative colitis
Current Research in Microbial Sciences·2025· 1 citedOpen Access
Co-existence of a novel RND efflux pump tmexC6D6.2-toprJ1b and blaOXA-4 in the extensively drug-resistant Pseudomonas aeruginosa ST233 clone
International Journal of Food Microbiology·2024· 2 cited
Comprehensive transcriptomic profiling of T-2 toxin-induced nephrotoxicity in mice
Ecotoxicology and Environmental Safety·2024· 2 citedOpen Access
Association analysis of antibiotic and disinfectant resistome in human and foodborne E. coli in Beijing, China
The Science of The Total Environment·2024· 8 cited
Abstract 5670: CRISPR-Mediated knockout of Ceruloplasmin (CP) and UCHL1 reveals angiogenic role in renal cell carcinoma (RCC) cell survival and proliferation
Cancer Research·2024
Supplementary Figures from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma
2023Open Access
Table S1 from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma
2023Open Access
Supplementary Figures from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma
2023Open Access
Table S3 from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma
2023Open Access
Table S5 from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma
2023Open Access
Table S4 from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma
2023Open Access
Supplementary Data 1 from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma
2023Open Access
Table S5 from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma
2023Open Access
Supplementary Data 1 from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma
2023Open Access
Data from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma
2023Open Access
Table S2 from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma
2023Open Access
Table S2 from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma
2023Open Access
Table S4 from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma
2023Open Access
Table S1 from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma
2023Open Access
Table S3 from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Li Ding(27), Matthew A. Wyczalkowski(26), Michael C. Wendl(18), Ruiyang Liu(17), Daniel Cui Zhou(16), Yize Li(16), Hui Zhang(16), Henry Rodriguez(14), Chia-Kuei Mo(13), Reyka G. Jayasinghe(12), Song Cao(12), Preet Lal(12), Liang-Bo Wang(11), James J. Hsieh(11), Mehdi Mesri(11), David Fenyö(11), Xiaolu Yang(11), R. Jay Mashl(10), Mathangi Thiagarajan(10), Ana I. Robles(10)